![PDF] Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer. | Semantic Scholar PDF] Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/e7d901374eddb6500e1e3f83e8039d512de691b3/2-Table1-1.png)
PDF] Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer. | Semantic Scholar
![P-121 Phase Ib trial of oxaliplatin, UGT1A1 genotype-directed dosing of irinotecan and chronomodulated capecitabine (OXIRI) chemotherapy in patients with advanced pancreatic cancer - Annals of Oncology P-121 Phase Ib trial of oxaliplatin, UGT1A1 genotype-directed dosing of irinotecan and chronomodulated capecitabine (OXIRI) chemotherapy in patients with advanced pancreatic cancer - Annals of Oncology](https://www.annalsofoncology.org/cms/asset/7b2ec333-e42f-4a7e-9488-8fd8e70c919b/fx1.jpg)
P-121 Phase Ib trial of oxaliplatin, UGT1A1 genotype-directed dosing of irinotecan and chronomodulated capecitabine (OXIRI) chemotherapy in patients with advanced pancreatic cancer - Annals of Oncology
![Cancers | Free Full-Text | Capecitabine in Combination with Endocrine Therapy as Maintenance Therapy after Bevacizumab Plus Paclitaxel Induction Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: KBCSG-TR1214 Cancers | Free Full-Text | Capecitabine in Combination with Endocrine Therapy as Maintenance Therapy after Bevacizumab Plus Paclitaxel Induction Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: KBCSG-TR1214](https://pub.mdpi-res.com/cancers/cancers-13-04399/article_deploy/html/images/cancers-13-04399-g001.png?1631173245)
Cancers | Free Full-Text | Capecitabine in Combination with Endocrine Therapy as Maintenance Therapy after Bevacizumab Plus Paclitaxel Induction Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: KBCSG-TR1214
![Capecitabine as Salvage Therapy for a Pancreatic Cancer Patient with Extensive Liver Metastases and Associated Impairment of Liver Function Capecitabine as Salvage Therapy for a Pancreatic Cancer Patient with Extensive Liver Metastases and Associated Impairment of Liver Function](https://www.primescholars.com/articles-images/pancreas-9-3-3-t001.png)
Capecitabine as Salvage Therapy for a Pancreatic Cancer Patient with Extensive Liver Metastases and Associated Impairment of Liver Function
![Initial Safety Analysis of CapeOx for Elderly Patients With Advanced Gastric Cancer Patients: A Phase II Trial | Anticancer Research Initial Safety Analysis of CapeOx for Elderly Patients With Advanced Gastric Cancer Patients: A Phase II Trial | Anticancer Research](https://ar.iiarjournals.org/content/anticanres/42/5/2683/F1.large.jpg)
Initial Safety Analysis of CapeOx for Elderly Patients With Advanced Gastric Cancer Patients: A Phase II Trial | Anticancer Research
![Capecitabine and Docetaxel Combination for the Treatment of Breast Cancer - Mariko Morishita, Robert C Leonard, 2008 Capecitabine and Docetaxel Combination for the Treatment of Breast Cancer - Mariko Morishita, Robert C Leonard, 2008](https://journals.sagepub.com/cms/10.2217/17455057.4.1.11/asset/images/large/10.2217_17455057.4.1.11-fig1.jpeg)